Nasus Pharma NSRX 深 沪
已收盘 11-06 16:00:00 美东时间
2.82
-0.090
-3.09%
华盛通- 最 高3.01
- 今 开2.82
- 成交量 7017股
- 最 低 2.78
- 昨 收 2.91
- 总市值 3303.29万
- 52周最高 9.50
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 1.98
- 委 比 33.33%
- 总股本 1171.38万
- 历史最高 9.9899
- 量 比 0.40
- 振 幅 7.90%
- 历史最低 1.98
- 每 手 1
- 风险率 1.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nasus Pharma收跌3.09%，成交额2.02万美元
11月7日，Nasus Pharma（NSRX）收跌3.09%，报2.82美元，成交额2.02万美元，市值3316.01万美元。 行情数据 • 开盘价：2.8...
11-07 08:30
美股大行评级 | 潜在涨幅332.55%！Viking Therapeutics获上调目标价至118美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至118美元；Canaccord Genuity：维持Aclaris Therapeutics"买入"评级，目标价从10美元升至13美元
11-02 18:53
Nasus Pharma收跌3.76%，成交额1.55万美元
10月31日，Nasus Pharma（NSRX）收跌3.76%，报3.07美元，成交额1.55万美元，市值3596.13万美元。 行情数据 • 开盘价：3....
10-31 07:31
Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7
Maxim Group analyst Naz Rahman initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $7.
10-30 21:32
Nasus Pharma收平，成交额5.26万美元
10月27日，Nasus Pharma（NSRX）收平，报3.49美元，成交额5.26万美元，市值4088.16万美元。 行情数据 • 开盘价：3.41美元 ...
10-27 07:30
Nasus Pharma收涨0.47%，成交额4.76万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:37
Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis Trial
Nasus Pharma Ltd. ( ($NSRX) ) has shared an announcement. On September 14, 2026...
09-14 20:47
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Nasus Pharma announced FDA clearance for its IND application for NS002, an investigational intranasal epinephrine powder for treating anaphylaxis. NS002 aims to serve as a needle-free alternative to EpiPen®. The company plans to initiate a pivotal study in Q4 2026, with top-line data expected in Q1 2027. CEO Brendan O'Grady highlighted NS002's potential to address unmet needs in severe allergy treatment, offering faster onset and a non-invasive a...
09-14 12:00
Nasus Pharma CFO Eyal Rubin to leave
Nasus Pharma (NSRX) on Wednesday said Chief Financial Officer, Eyal Rubin will be leaving the company to pursue a new opportunity outside the life science industry. Rubin will remain with Nasus throu...
08-19 19:05
Nasus Pharma Announces Transition of Chief Financial Officer
Nasus Pharma Ltd. announced that Chief Financial Officer Eyal Rubin will leave the company to pursue a new opportunity outside the life sciences industry. Rubin will remain with the company until September 18, 2026, to ensure a smooth transition. Oren Elmaliach, Director of Finance, has been appointed Interim CFO. Elmaliach has been with Nasus since its inception and has over 15 years of financial experience, including working with public and pri...
08-19 11:00
